CERO THERAPEUTICS HOLDINGS, INC. Noninterest Expense Investment Advisory Fees
CERO THERAPEUTICS HOLDINGS, INC. (CERO) reported Noninterest Expense Investment Advisory Fees of $1.16 million for the 12-month period ending 2023-12-31, per its 10-K filed 2024-04-02.
Discontinued › Expense Statement › Operating Expenses
us-gaap:NoninterestExpenseInvestmentAdvisoryFees · last filed 2024-04-02
- CERO THERAPEUTICS HOLDINGS, INC. noninterest expense investment advisory fees for fiscal 2023 was $1.16M.
| Period end | Noninterest Expense Investment Advisory Fees 12 month |
|---|---|
| 2023-12-31 | $1.16M 10-K · filed 2024-04-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (CELZ) | United States | $0.006B | |
| AIM ImmunoTech Inc. (AIM) | United States | $0.006B | |
| TScan Therapeutics, Inc. (TCRX) | United States | $0.008B | -1.23 |
| PharmaCyte Biotech, Inc. (PMCB) | United States | $0.005B | |
| WINDTREE THERAPEUTICS INC /DE/ (WINT) | United States | $0.003B | -0.32 |
| VivoSim Labs, INC. (VIVS) | United States | $0.003B | |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |
| Calidi Biotherapeutics, Inc. (CLDI) | United States | $0.003B | |
| IN8BIO, INC. (INAB) | United States | $0.012B | -0.76 |
| CURIS INC (CRIS) | United States | $0.002B | -0.05 |